Previous 10 | Next 10 |
Meridian Bioscience (NASDAQ:VIVO): FQ3 Non-GAAP EPS of $0.22 misses by $0.09; GAAP EPS of $0.27 misses by $0.05. Revenue of $63.51M (-25.1% Y/Y) misses by $9.61M. Press Release For further details see: Meridian Bioscience EPS misses by $0.09, misses on revenue
CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020): • Consolidated net revenues of $63....
CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek ® business from Ots...
Meridian Bioscience ([[VIVO]]) has signed a definitive agreement to acquire the North American BreathTek business from Otsuka America Pharmaceutical for $20M in cash.The transaction is expected to close in Meridian’s fiscal Q4. With this acquisition, Meridian will assume the customer r...
CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek ® business from Otsuka Am...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July
CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021. Jack Kenny, Chief Executive Officer, and B...
Gainers: Allied Healthcare Products (AHPI) +107%, SCWorx (WORX) +32%, Longboard Pharmaceuticals (LBPH) +18%, Dynatronics (DYNT) +14%, Shineco (TYHT) +13%.Losers: Meridian Bioscience (VIVO) -18%, Aridis Pharmaceuticals (ARDS) -17%, Simulat...
Meridian Bioscience (VIVO) down 2.4% premarket after providing preliminary revenue results for fiscal Q3 2021. The company expects Q3 revenue to be ~$63.5M, below consensus of $73.12M.The Diagnostics segment performance was impacted negatively by supply chain issues w...
CINCINNATI, July 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. Preliminary unaudited revenue for the thi...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...